Your session is about to expire
← Back to Search
Aminopeptidase inhibitor
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
Phase 2
Waitlist Available
Research Sponsored by Chroma Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up protocol-mandated visits every 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to evaluate the long-term efficacy and safety profile of tosedostat in elderly patients suffering from refractory or relapsed Acute Myeloid Leukemia.
Eligible Conditions
- Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ protocol mandated visits every 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~protocol mandated visits every 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and Tolerability of extended treatment with tosedostat
Secondary study objectives
Efficacy of extended treatment with tosedostat
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: TosedostatExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tosedostat
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Chroma TherapeuticsLead Sponsor
9 Previous Clinical Trials
344 Total Patients Enrolled